Peginterferon alfa-2b (Sylatron)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 06:41, 13 May 2012 by Dryang (talk | contribs) (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>")
Jump to navigation Jump to search

Also known as Sylatron.

General information

Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Also has been seen to activate NFκB (NF kappa B) in many cell types. Interferon α-2b activates multiple biologic effects which are not fully understood. Pegylation results in a longer half-life compared to Interferon alfa-2b (Intron-A).[1][2]
Route: SC
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References

  1. ↑ 1.0 1.1 Peginterferon alfa-2b (PegIntron) package insert
  2. ↑ Peginterferon alfa-2b (PegIntron) package insert (locally hosted backup)
  3. ↑ Peginterferon alfa-2b (PegIntron) patient drug information (Chemocare)
  4. ↑ Peginterferon alfa-2b (PegIntron) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Peginterferon_alfa-2b_(Sylatron)&oldid=1495"